23andMe
Bookmark
ShareCopied to clipboard23andMe is a company. It is a private company in South San Francisco, the United States. It was founded in 2006 and its current CEO is Anne Wojcicki. It is part of the Health Care sector, specifically in the Health Care Technology industry.
Key facts
- city: South San Francisco
- country: United States
- employees: 560 people
- revenues: 208.8M $
- company type: private
- sector: Health Care
- industry: Health Care Technology
- foundation year: 2006
- CEO: Anne Wojcicki
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about 23andMe:
Dataset of stocks from 23andMe:
23andMe is one of the companies in the United States, companies in Health Care Technology, companies in Health Care, companies in South San Francisco and 3,456,808 companies in our database.
Talking Points
- DNA Genetic Testing For Health, Ancestry And More23andMe
- 23andMe offers DNA testing with the most comprehensive ancestry breakdown, personalized health insights and more.
- DNA Genetic Testing For Health, Ancestry And More - 23andMe United Kingdom
- Your DNA has a lot to say about your health, traits and ancestry. For help, tweet us @23andMesupport.
- Our mission is to help people access, understand and benefit from the human genome. | 23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company's mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as ...
- 23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.